AMATO, Marco Calogero
 Distribuzione geografica
Continente #
NA - Nord America 10.201
EU - Europa 6.120
AS - Asia 5.145
SA - Sud America 684
AF - Africa 194
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 5
Totale 22.373
Nazione #
US - Stati Uniti d'America 10.056
SG - Singapore 1.801
CN - Cina 1.343
RU - Federazione Russa 1.297
IT - Italia 1.058
FI - Finlandia 1.016
DE - Germania 658
HK - Hong Kong 544
UA - Ucraina 536
BR - Brasile 529
VN - Vietnam 456
IE - Irlanda 347
PL - Polonia 307
FR - Francia 272
GB - Regno Unito 246
JP - Giappone 243
KR - Corea 133
BD - Bangladesh 118
SE - Svezia 113
IN - India 99
TR - Turchia 91
IQ - Iraq 61
MX - Messico 57
CA - Canada 56
BE - Belgio 55
CI - Costa d'Avorio 55
RO - Romania 55
AR - Argentina 48
NL - Olanda 37
MA - Marocco 34
ZA - Sudafrica 30
CL - Cile 25
ES - Italia 24
KE - Kenya 23
AU - Australia 22
AT - Austria 21
EC - Ecuador 20
AE - Emirati Arabi Uniti 19
NP - Nepal 19
PK - Pakistan 19
UZ - Uzbekistan 17
JO - Giordania 16
VE - Venezuela 16
CO - Colombia 15
CZ - Repubblica Ceca 15
DZ - Algeria 15
MY - Malesia 15
SA - Arabia Saudita 15
ID - Indonesia 14
IR - Iran 14
EG - Egitto 13
CH - Svizzera 12
PH - Filippine 12
PY - Paraguay 12
AL - Albania 10
GR - Grecia 10
AZ - Azerbaigian 9
BH - Bahrain 9
IL - Israele 9
LB - Libano 9
TN - Tunisia 9
TW - Taiwan 9
CR - Costa Rica 8
HN - Honduras 8
KZ - Kazakistan 8
PE - Perù 8
SY - Repubblica araba siriana 8
UY - Uruguay 8
KG - Kirghizistan 6
LT - Lituania 6
BG - Bulgaria 5
DO - Repubblica Dominicana 5
OM - Oman 5
EU - Europa 4
MK - Macedonia 4
PS - Palestinian Territory 4
TH - Thailandia 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
BY - Bielorussia 3
CY - Cipro 3
DK - Danimarca 3
JM - Giamaica 3
KW - Kuwait 3
RS - Serbia 3
AM - Armenia 2
GE - Georgia 2
HU - Ungheria 2
LY - Libia 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
QA - Qatar 2
SV - El Salvador 2
TZ - Tanzania 2
AO - Angola 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CG - Congo 1
Totale 22.359
Città #
Ashburn 1.242
Singapore 1.154
Fairfield 922
Chandler 602
Hong Kong 534
Woodbridge 485
Wilmington 481
Ann Arbor 458
San Jose 450
Houston 430
Seattle 375
Dublin 347
Jacksonville 333
Cambridge 317
Zgierz 268
Council Bluffs 240
Tokyo 239
Moscow 221
Helsinki 220
Medford 212
Beijing 205
Frankfurt am Main 198
Palermo 196
Des Moines 176
Ho Chi Minh City 163
Santa Clara 159
Nanjing 158
New York 147
Boardman 141
Princeton 135
Los Angeles 125
Lauterbourg 111
Hanoi 110
Munich 107
Dallas 105
Dearborn 94
Tulsa 83
Altamura 82
The Dalles 82
Shenyang 70
Jinan 66
San Diego 66
Changsha 60
Nanchang 56
Tianjin 56
Abidjan 55
Brussels 55
Chicago 54
Lawrence 53
Milan 51
Phoenix 50
Buffalo 48
São Paulo 47
Izmir 44
Hebei 41
Atlanta 38
Zhengzhou 38
London 37
Ningbo 36
Guangzhou 33
Jiaxing 31
Baghdad 27
Kumar 27
Orem 27
Auburn Hills 26
Frankfurt 26
Falls Church 25
Hangzhou 25
Paris 25
Taizhou 24
Verona 24
Da Nang 23
Saint Petersburg 23
Nuremberg 22
Seongnam 21
Warsaw 21
Hefei 20
Venice 20
City of London 18
Columbus 18
Nairobi 18
Santiago 18
Taiyuan 18
Amsterdam 17
Ankara 17
Rio de Janeiro 17
Rome 17
Denver 16
Erbil 16
Amman 15
Boston 15
Bucheon-si 14
Montreal 14
San Paolo di Civitate 14
Brooklyn 13
Haiphong 13
Johannesburg 13
Lanzhou 13
Mexico City 13
Stockholm 13
Totale 13.938
Nome #
BRAFV600E mutation, TIMP-1 up-regulation and NF-{kappa}B activation: closing the loop on the papillary thyroid cancer trilogy. 333
Predictors of microvascular complications in type 1 diabetic patients at onset: The role of metabolic memory 328
Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. 313
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 298
In vitro identification and characterization of CD133pos cancer stem-like cells in anaplastic thyroid carcinoma cell lines 290
Anaplastic Thyroid Carcinoma: A ceRNA Analysis Pointed to a Crosstalk between SOX2, TP53, and microRNA Biogenesis. 283
Visceral Adiposity Index: An Indicator of Adipose Tissue Dysfunction 280
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study 270
Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index 267
Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency 265
BRAFV600E Mutation and p27kip1 Expression in Papillary Carcinomas of the Thyroid ≤1 cm and Their Paired Lymph Node Metastases 260
Oligomenorrhea in PCOS is characterized by a high visceral adiposity index (VAI): a likely condition of cardiometabolic risk. 258
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 253
Fine-Needle Aspiration (FNAB) Molecular Analysis for the Diagnosis of Papillary Thyroid Carcinoma through BRAFv600E mutation and RET/PTC rearrangement 249
Development of a fuzzy expert system for the control of glycemia in type 1 diabetic patients 242
The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome 238
Cornea in acromegalic patients as a possible target of growth hormone action. 234
OCT is not useful for detection of minimal diabetic retinopathy in type 1 diabetes. 232
Serum miRNAs in women affected by hyperandrogenic polycystic ovary syndrome: the potential role of miR-155 as a biomarker for monitoring the estroprogestinic treatment 232
Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. 229
The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome 223
Visceral Adiposity Index Is Associated with Insulin Sensitivity and Adipocytokine Levels in Newly Diagnosed Acromegalic Patients. 222
Body composition assessment for the definition of cardiometabolic risk. 220
Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: efficacy of octreotide therapy 219
Visceral Adiposity Index (VAI) Is Predictive of an Altered Adipokine Profile in Patients with Type 2 Diabetes 218
Clamp euglicemico iperinsulinemico e test al glucagone come utili strumenti di valutazione degli effetti metabolici della terapia sostitutiva con GH. 213
Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome 209
Use of Glargine in Pregnant Women with Type 1 Diabetes Mellitus: A Case-Control Study 207
Visceral Adiposity Index (VAI): A Reliable Indicator Of Visceral Fat Function Associated With Cardiometabolic Risk. 205
Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. 205
Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. 204
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. 202
Il c-peptide come marker principale nella storia naturale del Diabete tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze 201
Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. 198
Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein. 198
BRAFV660E mutation and Timp-1 hyper-expression in classical variants of papyllary thyroid carcinoma. 195
Valutazione dell'insulinoresistenza tramite un test pasto standard 193
BRAFV600E mutation and timp-1 hyper-expression in classical variants of papillary thyroid carcinoma (PTC). 193
Relative Hypoleptinemia in poor controlled patients with Type 1 Diabetes 191
The Metabolic Profile in Active Acromegaly is Gender-Specific. 190
Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. 190
Espressione dei fattori di trascrizione di staminalità in cellule stromali (HASC) ottenute da tessuto adiposo viscerale e sottocutaneo 187
Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? 184
Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome. 184
Alterazioni del metabolismo glucidico determinate da eccesso di ormoni controregolatori: ruolo del GH 184
Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis 181
Clinical indications and proper use of Visceral Adiposity Index. 179
Changes in lipid profile and adipokine levels in GH deficient children during GH replacement therapy. 177
Correlation between Severity of Growth Hormone Deficiency and Thyroid Metabolism and Effects of Long-Term Growth Hormone Treatment on Thyroid Function in Children with Idiopathic Growth Hormone Deficiency. 174
Adrenal incidentaloma: a new contributing factor in metabolic syndrome 172
Endocrine and pro-inflammatory activity of visceral (VAT) and subcutaneous (SAT) adipose tissue in morbidly obese patients with and without metabolic syndrome. 172
No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus. 172
Sviluppo di un sistema di supporto decisionale tipo Fuzzy per il controllo della glicemia post-prandiale nel diabete mellito tipo 1 171
Visceral Adiposity Index (VAI) as a simple indicator of “adipose tissue dysfunction” in patients with type 2 diabetes. 169
THE CLINICAL ACTIVITY SCORE IN MANAGEMENT OF GRAVES’ OPHTHALMOPATHY: CORRELATION WITH ORBITAL MR IMAGING. 169
Safety of glargine therapy during pregnancy in women with type 1 diabetes mellitus. 168
Alta prevalenza di Sindrome dell’ovaio policistico in donne diabetiche di tipo 1 in età fertile. 168
Alte dosi di cabergolina migliorano i parametri metabolici in pazienti affetti da prolattinoma. 168
Alterazioni del metabolismo glucidico determinate da eccesso di ormoni contro regolatori. 167
Variabili cliniche nella casistica del policlinico di Palermo nell’ambito del registro dei tumori della tiroide in Sicilia: Età, sesso, autoimmunità, tipo, dimensionilesionali e coinvolgimento delle stazioni linfonodali della tiroide 166
GH-suppression test in acromegaly: comparison between OGTT and chocolate test 165
Rotterdam consensus, NIH and EAS: comparison among the three different diagnostic criteria for the diagnosis of PCOS. 165
Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA). 165
Glycometabolic control in Acromegalic patients with Diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. 164
Adrenal incidentaloma: a new contributing factor in metabolic syndrome? 164
Leptina e adiponectina nella valutazione del compenso glicometabolico in corso di diabete mellito di tipo 1 normopeso. 163
No effect of GH/IGF-1 excess on adrenal glands in acromegalic patients 162
L’uso del hrTSH nel follow up del microcarcinoma tiroideo in pazienti sottoposti a tiroidectomia totale 162
Effetti della terapia combinata (OHA+Insulina) su una casistica ambulatoriale di pazienti affetti da NIDDM. 162
Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency 161
Detection of BRAFV600 mutation in papillary thyroid carcinoma using real time allele-specific amplification on fine needle aspiration biopsy specimens 160
Buon compenso glicemico nei pazienti acromegalici affetti da diabete secondario. 160
Detection of BRAFv600E mutation in papillary thyroid carcinoma using real time allele-specific amplification on fine needle aspiration biopsy specimens. 158
Neck liymph nodes in chronic autoimmune thyroiditis: the sonographic pattern. 157
AlKam Metabolic Syndrome Study (AlkaMeSy Study): Studio di prevalenza sulla sindrome metabolica. 156
Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations 156
Prevalenza del cancro del colon e di altre neoplasie in una casistica ambulatoriale di soggetti affetti da diabete mellito tipo 2. 154
The use of rh-TSH in the follow-up of thyroid microcarcinoma after total thyroidectomy 152
Utilizzo del Visceral Adiposity Index per l’identificazione di donne con sindrome iperandrogenica a rischio cardiometabolico. 152
The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. 151
Marcatori di rischio diabetologico nella Sindrome dell’ovaio policistico (PCOS). 151
Visceral Adipose function, insulin sensitivity and secretion in active acromegaly. 147
Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment 147
Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. 145
Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome 145
Off-line control of the postprandial glycemia in type 1 diabetes patients by a fuzzy logic decision support 144
Complete biochemical control and oituitary adenoma disappearance in a child with gigantism: efficay of octreotide therapy 140
Low Estradiol-to-Testosterone ratio is associated with low progesterone levels and atherogenic lipidic pattern in women with policystic ovary syndrome (PCOS). 140
Increased central corneal thickness in acromegalic patients. 140
The sonographic pattern of neck lymph nodes in chronic autoimmune thyroiditis. 140
Effetti di una terapia con glucocorticoidi ev ad alte dosi sull'oftalmopatia di Graves moderata-severa:uno studio caso-controllo 140
Fenotipizzazione del diabete mellito tipo 2 all’esordio, basata sul tono incretinico a digiuno: risultati di una two-step cluster analysis. 137
The adipose visceral dysfunction plays an important role in diabetes in Cushing disease. 137
Variazioni plasmatiche del fattore di crescita insulino-simile (IGF-1) durante iperinsulinizzazione esogena (calmp euglicemico) in pazienti affetti da sindrome metabolica con e senza complicanze macrovascolari. 136
Insulin sensitivity and visceral adiposity index (VAI) in women with functional secondary amenorrhea. 133
Use of basal insulin analog detemir in pregnant women with type 1 diabetes: a case-control retrospective study 133
Effetti di un’infusione insulinica di breve durata in diabetici tipo 2 non obesi in “secondary failure” alle sulfaniluree. 132
HYPERINSULINISM AND POLYCYSTIC OVARY SYNDROME (PCOS): ROLE OF INSULIN CLEARANCE. 132
Low hrTSH-Tg levels in patients affected by papillary thyroid microcarcinoma are influenced by pre-surgery L-thyroxine therapy. 131
Adrenal morphology and function in acromegalic patients in relation to disease activity. 130
Totale 18.931
Categoria #
all - tutte 71.373
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.373


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021162 0 0 0 0 0 0 0 0 0 0 0 162
2021/20221.485 42 323 35 48 87 63 64 65 151 196 109 302
2022/20231.847 233 265 35 178 231 303 132 130 223 15 77 25
2023/2024704 42 153 45 53 44 172 40 57 3 8 10 77
2024/20252.238 76 102 154 214 67 82 144 231 158 213 314 483
2025/20268.388 526 204 368 523 713 1.271 1.259 819 652 1.525 362 166
Totale 22.938